RxDoctor Payments Data

Matthias Linke, DO

Physical Medicine & Rehabilitation · Phoenix, AZNPI 1811035025

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 28.6% of the total.

$640in general payments, 2019–2025

Across 30 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$183
  • Philips North America LLC$158
  • AbbVie$99
  • 180 Medical, Inc.$76
  • Coloplast$58
  • Amneal Pharmaceuticals LLC$51
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$640100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$640 in reported general payments places this provider in the 60th percentile of 162 physical medicine & rehabilitation providers in Arizona.

See all physical medicine & rehabilitation providers in Arizona

Medicare billing

Part B allowed, 2024
$126,896
Medicare patients
284
Services billed
1,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina116$321,353
DysportAbobotulinumtoxina17$31,470
Baclofen367$11,086
Gabapentin248$4,830
Pregabalin117$3,930
Midodrine Hcl39$2,625
Dantrolene Sodium43$2,431
Methocarbamol65$1,956
Oxybutynin Chloride63$1,513
Tizanidine Hcl65$1,500
Trospium Chloride13$1,197
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$1,105
Duloxetine Hcl73$950
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$830
Cyclobenzaprine Hcl40$559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$99$321,353116 claims
Ipsen Biopharmaceuticals, IncDysport$183$31,47017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 162 physical medicine & rehabilitation providers in Arizona.

Other physical medicine & rehabilitation in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →